OVERVIEW
Gene expression profile analysis and protein biomarkers have been proposed as a means to risk-stratify patients with prostate cancer to guide treatment decisions. These tests are intended to be used either on prostate needle biopsy tissue to guide management decisions for active surveillance or therapeutic intervention, to guide radiotherapy use after radical prostatectomy (RP), or to guide medication selection after progression in metastatic castration-resistant prostate cancer.

MEDICAL CRITERIA
BlueCHiP for Medicare

OncotypeDX
The Oncotype DX® Prostate Cancer Assay is covered only when the following clinical conditions are met:
• Needle biopsy with localized adenocarcinoma of prostate (no clinical evidence of metastasis or lymph node involvement), and
• Patient stage as defined by the one of the following:
  ◦ Very Low Risk Disease (T1c AND Gleason Score = 6 AND PSA = 10 ng/mL)
  ◦ Low Risk Disease (T1-T2a AND Gleason Score = 6 AND PSA = 10 ng/mL), and
• Patient has an estimated life expectancy of ≥ 10 years, and
• Patient is a candidate for and is considering conservative therapy and yet would be eligible for definitive therapy (radical prostatectomy, radiation therapy or brachytherapy), and
• Patient has not received pelvic radiation or androgen deprivation therapy prior to the biopsy, and
• Test is ordered by a physician certified in the Genomic Health™ Oncotype DX® Prostate Cancer Assay Certification and Training Registry (CTR), and
• Patient is monitored for disease progression according to active surveillance guidelines as recorded in NNCN guidelines.

OncotypeDX AR-V7 Nuclear Detect
OncotypeDX AR-V7 Nuclear Detect assay is covered when the following clinical conditions are met:
• Patient has progressive mCRPC as defined by the Prostate Cancer Working Group 2 guidelines (a minimum of 2 rising prostate-specific antigen (PSA) levels 1 or more weeks apart, new lesions by bone scintigraphy, and/or new or enlarging soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI)).
• Patient has failed one androgen receptor signaling inhibitor (ARSi), specifically Enzalutamide (Xtandi), Apalutamide (Erleada), or Abiraterone (Zytiga).
• Patient is considered appropriate for treatment by their treating physician for the alternative ARSi as a single agent.
• Circulating tumor cells (CTC) with nuclear expression of AR-V7 protein have been assessed prior to initiation of therapy.

Commercial Products
Unless otherwise noted, for any test filed with an Unlisted CPT code, the medical necessity criteria in the Genetic Testing Services policy would be used. Please see the Related Policies section.

PRIOR AUTHORIZATION
BlueCHiP for Medicare
Prior authorization is required for the Oncotype DX® Prostate Cancer Assay and OncotypeDX AR-V7 Nuclear Detect assay and is obtained via the online tool for participating providers.

**BlueCHiP for Medicare and Commercial Products**

Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial products and is obtained via the online tool for participating providers. See the Related Policies section.

There is no specific CPT coding for some testing referenced in this policy. Therefore, an Unlisted CPT code should be used (See Coding Section for details). All Unlisted genetic testing CPT codes require prior authorization to determine what service is being rendered and if the service is covered or not medically necessary. See the Related Policies section.

**POLICY STATEMENT**

**BlueCHiP for Medicare**

The Oncotype DX prostate cancer assay and OncotypeDX AR-V7 Nuclear Detect assay will be considered medically necessary when the medical criteria listed above are met.

Use of gene expression analysis and protein biomarkers to guide management of prostate cancer, other than Oncotype DX prostate cancer assay and OncotypeDX AR-V7 Nuclear Detect assay, is not covered in all situations as the evidence is insufficient to determine the effects of the technology on health outcomes.

**Commercial Products**

Use of any gene expression analysis and protein biomarkers to guide management of prostate cancer is considered not medically necessary in all situations as the evidence is insufficient to determine the effects of the technology on health outcomes.

**COVERAGE**

Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable genetic testing and not medically necessary/not covered benefits/coverage.

**BACKGROUND**

**BlueCHiP for Medicare and Commercial Products**

Prostate cancer is the second most common noncutaneous cancer diagnosed among men in the United States. Autopsy studies in the era before the availability of prostate-specific antigen (PSA) screening have identified incidental cancerous foci in 30% of men 50 years of age, with incidence reaching 75% at age 80 years.

Localized prostate cancers may appear very similar clinically at diagnosis. However, they often exhibit diverse risk of progression that may not be captured by clinical risk categories (eg, D’Amico criteria) or prognostic tools based on clinical findings, including PSA titers, Gleason grade, or tumor stage. In studies of conservative management, the risk of localized disease progression based on prostate cancer–specific survival rates at 10 years may range from 15% to 20% to perhaps 27% at 20-year follow-up. Among older men (ages ≥ 70 years) with low-risk disease, comorbidities typically supervene as a cause of death; these men will die with prostate cancer present, rather than from cancer itself. Other very similar appearing low-risk tumors may progress unexpectedly rapidly, quickly disseminating and becoming incurable.

**Risk Stratification in Newly Diagnosed Disease**

In the United States, most prostate cancers are clinically localized at diagnosis due in part to the widespread use of PSA testing. Clinicopathologic characteristics are used to stratify patients by risk based on the extent of the primary tumor (T category), nearby lymph node involvement (N category), metastasis (M category), PSA level and Gleason score. The National Comprehensive Cancer Network and American Urological Association risk categories for clinically localized prostate cancer are similar, derived from the D’Amico criteria and broadly include low-, intermediate-, or high-risk as follows as well as subcategories within these groups:
- Low: T1-T2a and Gleason score ≤6/Gleason grade group 1 and PSA level ≤10 ng/mL;
- Intermediate: T2b-T2c or Gleason score 3+4=7/Gleason grade group 2 or Gleason score 4+3=7/Gleason grade group 3 or PSA level 10-20 ng/mL;
- High: T3a or Gleason score 8/Gleason grade group 4 or Gleason score 9-10/Gleason grade group 5 or PSA level >20 ng/mL.

Risk stratification is combined with patient age, life expectancy, and treatment preferences to make initial therapy decisions.

**Monitoring After Prostatectomy**

All normal prostate tissue and tumor tissue is theoretically removed during radical prostatectomy (RP), so the serum level of PSA should be undetectable following RP. Detectable PSA post-RP indicates residual prostate tissue and presumably persistent or recurrent disease. PSA is serially measured following RP to detect early disease recurrence. The National Comprehensive Cancer Network recommends monitoring serum PSA every 6 to 12 months for the first 5 years and annually thereafter. Many recurrences following RP can be successfully treated. The American Urological Association has recommended that biochemical recurrence be defined as a serum PSA of 0.2 ng/mL or higher, which is confirmed by the second determination with a PSA level of 0.2 ng/mL or higher.

**Castration-Resistant Prostate Cancer**

Androgen deprivation therapy (ADT) is generally the initial treatment for patients with advanced prostate cancer. ADT can produce tumor response and improve quality of life but most patients will eventually progress on ADT. Disease that progresses while the patient is on ADT is referred to as castration-resistant prostate cancer. After progression, continued ADT is generally used in conjunction with other treatments. Androgen pathways are important in the progression of castration-resistant prostate cancer. Several drugs have been developed that either inhibit enzymes involved in androgen production or inhibit the androgen receptor, such as abiraterone and enzalutamide. Taxane chemotherapy with docetaxel or cabazitaxel may also be used after progression. Immunotherapy (sipuleucel-T) or radium 223 are options for select men.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Prolaris® (Myriad Genetics), Oncotype DX® Prostate and Oncotype DX AR-V7 Nuclear Detect (Genomic Health), Decipher® gene expression profiling test (Genome Dx Biosciences), and the ProMark™ protein biomarker test (Genomic Health) are available under the auspices of CLIA. Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

**Prolaris**

Prolaris is used to quantify expression levels of 31 cell cycle progression (CCP) genes and 15 housekeeper genes to generate a CCP score.

For individuals who have low- or intermediate-risk clinically localized untreated prostate cancer who receive Prolaris, the evidence includes studies includes retrospective cohort studies of clinical validity using archived samples in patients of mixed risk categories. Relevant outcomes include overall survival, disease-specific survival, quality of life, and treatment-related morbidity. For the low-risk group, the Prostate Testing for Cancer and Treatment (ProtecT) trial showed 99% ten-year disease-specific survival in mostly low-risk patients receiving active surveillance. The low mortality rate estimated with tight precision makes it unlikely that a test intended to identify a subgroup of low-risk men with a net benefit from immediate treatment instead of active surveillance would find such a group. For the intermediate-risk group, the evidence of improved clinical validity or prognostic accuracy for prostate cancer death using Prolaris Cell Cycle Progression score in patients managed conservatively after needle biopsy has shown some improvement in areas under the receiver operating characteristic curve over clinicopathologic risk stratification tools. There is
limited indirect evidence for potential clinical utility. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have localized prostate cancer treated with RP who receive Prolaris, the evidence includes retrospective cohort studies of clinical validity using archived samples. Relevant outcomes include overall survival, disease-specific survival, quality of life, and treatment-related morbidity. Evidence of improved clinical validity or prognostic accuracy for prostate cancer death using the Prolaris Cell Cycle Progression score in patients after prostatectomy has shown some improvement in areas under the receiver operating characteristic curve over clinopathologic risk stratification tools. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Oncotype DX Prostate**

Oncotype DX® Prostate Cancer Assay is prostate biopsy-based 17-gene RT-PCR assay, representing four molecular pathways (androgen signaling, cellular organization, stromal response and proliferation), that provides a biologic measure of cancer aggressiveness. The assay is indicated for men who are considered candidates for active surveillance (AS) (those with NCCN® very low- and low-risk prostate cancer). The assay is designed to inform decisions between AS and immediate treatment.

**BlueCHiP for Medicare**

The potential usefulness of this test is that it allows physicians to determine which patients with early prostate cancer are candidates for active surveillance and are more likely to have a good outcome without needing to receive definitive treatment.

**Commercial Products**

For individuals who have low- or intermediate-risk clinically localized untreated prostate cancer who receive Oncotype DX Prostate, the evidence includes case-cohort and retrospective cohort studies of clinical validity using archived samples in patients of mixed risk categories, and a decision-curve analysis examining indirect evidence of clinical utility. Relevant outcomes include overall survival, disease-specific survival, quality of life, and treatment-related morbidity. Evidence for clinical validity and potential clinical utility of Oncotype DX Prostate in patients with clinically localized prostate cancer derives from a study predicting adverse pathology after RP. The validity of using tumor pathology as a surrogate for risk of progression and cancer-specific death is unclear. It is also unclear whether results from an RP population can be generalized to an active surveillance population. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Oncotype DX AR-V7 Nuclear Detect**

Oncotype DX AR-V7 Nuclear Detect is used to detect nuclear-localized AR-V7 protein in CTCs of men with mCRPC who have failed first-line therapy and are considering additional ARS inhibitor therapy.

**For BlueCHiP for Medicare**

Men with metastatic castration resistant prostate cancer (mCRPC) have multiple life extending, FDA-approved therapeutics options. However, there is no clear consensus on the therapeutic sequencing after initial exposure to an androgen receptor signaling inhibitor (ARSi), such as apalutamide, abiraterone or enzalutamide. The response rate for a second ARSi, Abiraterone after Enzalutamide, or Enzalutamide after Abiraterone is lower than the initial exposure. Therefore, the most common clinical decision focuses on whether to start a second ARSi or taxane chemotherapy. It is therefore important to identify patients who will not respond to a 2nd ARSi in order to 1) avoid giving an ineffective therapy, and 2) delaying giving a more effective therapy, such as taxane chemotherapy, taxane combination therapies, Radium-223, PARP inhibitors, and platinum chemotherapy.

AR-V7 protein results from alternative androgen receptor (AR) mRNA splicing, which produces a constitutively active receptor that is associated with resistance to ARSi such as abiraterone and enzalutamide. A growing body of evidence suggests that patients with ARV7 positive mCRPC do not benefit from ARSi therapy but may respond to taxanes, such as docetaxel.3-5 Supporting observations include that 1) AR-V7
positivity is associated with resistance to androgen receptor-targeted therapies; 2) taxanes are equally effective in AR-V7–positive and AR-V7–negative mCRPC patients; and 3) AR-V7 status may change during therapy. For these reasons, the National Comprehensive Cancer Network (NCCN) suggests that AR-V7 is a biomarker that may help guide therapy in mCRPC.

AR signaling requires that the AR transcriptional elements bind to DNA within the nucleus of the cancer cell. Therefore, the nuclear localization of the AR-V7 truncated protein may improve the clinical specificity of predicting ARSi resistance. Analysis of AR-V7 localization scoring guides has demonstrated that only nuclear AR-V7 protein expression improves the clinical specificity of predicting ARSi resistance, and importantly, is associated with improved overall survival with taxane chemotherapy.

It is expected that < 15% of nuclear AR-V7-positive patients will receive an ARSi and that nuclear AR-V7-negative patients who receive an ARSi will have a similar or better time on therapy than untested mCRPC patients (meeting above criteria) receiving ARSi.

**Commercial Products**

For individuals who have metastatic castration-resistant prostate cancer who receive the Oncotype DX AR-V7 Nuclear Detect, the evidence includes a retrospective cohort study of clinical validity using archived samples, and no studies of clinical utility. Relevant outcomes include overall survival, diseasespecific survival, quality of life, and treatment-related morbidity. Current evidence does not support improved outcomes with Oncotype DX AR-V7 Nuclear Detect, given that only a single clinical validity study, meeting inclusion criteria was available. The evidence is insufficient to determine the effects of the technology on health outcomes.

**ProMark Protein Biomarker Test**

The ProMark assay includes 8 biomarkers that predict prostate pathology aggressiveness and lethal outcomes: DERL1, PDSS2, pS6, YBX1, HSPA9, FUS, SMAD4, and CUL2. The assay results are combined using predefined coefficients for each marker from a logistic regression model to calculate a risk score. The risk score is a continuous number between 0 and 1, which estimates the probability of “non–GS 6” pathology.

For individuals who have low- or intermediate-risk clinically localized untreated prostate cancer who receive the ProMark protein biomarker test, the evidence includes a retrospective cohort study of clinical validity using archived samples and no studies of clinical utility. Relevant outcomes include overall survival, diseasespecific survival, quality of life, and treatment-related morbidity. Current evidence does not support improved outcomes with ProMark given that only a single clinical validity study is available. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Decipher Prostate Cancer Classifier**

The Decipher test classifies as low risk those patients who can delay or defer RT after prostatectomy, or as high risk those who would potentially benefit from early radiation. The GC is a continuous risk score between 0 and 1, with higher risk scores indicating a greater probability of developing metastasis.

For individuals who have localized prostate cancer who are treated with RP and who receive the Decipher prostate cancer classifier, the evidence includes a study of analytic validity, prospective and retrospective studies of clinical validity using overlapping archived samples, decision-curve analyses examining indirect evidence of clinical utility, and prospective decision-impact studies without pathology or clinical outcomes. Relevant outcomes include overall survival, diseasespecific survival, quality of life, and treatment-related morbidity. The clinical validity of the Decipher genomic classifier has been evaluated in samples of patients with high-risk prostate cancer undergoing different interventions following RP. Studies reported some incremental improvement in discrimination. However, it is unclear whether there is consistently improved reclassification—particularly to higher risk categories—or whether the test could be used to predict which men will benefit from radiotherapy. The evidence is insufficient to determine the effects of the technology on health outcomes.
The following CPT code is not covered for BlueHiP for Medicare and not medically necessary for Commercial Products. This code can be used for the Prolaris® PCA3 Assay.

81541 Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score

The following code requires prior authorization for BlueHiP for Medicare and is not medically necessary for Commercial Products. This code can be used for the Oncotype DX® Prostate Cancer Assay.

0047U Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score

The following Unlisted CPT code requires prior authorization for BlueHiP for Medicare and Commercial Products. The code can be used for any test identified in this policy that does not have a specific CPT code.

81479 Unlisted molecular pathology procedure

RELATED POLICIES
Genetic Testing Services
Proprietary Laboratory Analyses (PLA)

PUBLISHED
Provider Update, August 2019
Provider Update, November 2017
Provider Update, September 2016
Provider Update, December 2015

REFERENCES
2. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000)
This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.